MSLE NASDAQ
Satellos Bioscience Inc. Common Stock
1W: -0.4%
1M: -4.2%
3M: -36.5%
YTD: +0.8%
$6.75
-0.39 (-5.46%)
Weekly Expected Move ±12.1%
$5
$6
$7
$8
$9
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.7M
52W Range4.524-13.395
Volume58,316
Avg Volume76,708
Beta1.57
Dividend—
Analyst Ratings
Company Info
CEOFrancis Gleeson
Employees14
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2024-05-10
Websitesatellos.com
Royal Bank Plaza
Toronto, ON M5J 2J1
CA
Toronto, ON M5J 2J1
CA
1 647 660 1780
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX⢠and Leveraging MyoReGenXâ¢, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.
Latest News
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
Satellos Bioscience GAAP EPS of -$1.70
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Recent Insider Trades
No insider trades found